Moreover, the first humanized anti-CCR7 antibody was approved for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (NCT04704323), highlighting CCR7’s potential as a key target in cancer therapy. Here, CCR7 is linked to B-cell chronic lymphocytic leukemia.